Rainbow Childrens Medicare Ltd (RAINBOW)
🎯 Key Takeaways
- Rainbow Children's Medicare is in a high-growth phase, executing a disciplined expansion strategy to scale its pediatric super-specialty network from 1,862 to 5,000 beds by 2031. Management is targeting 20% annual revenue growth through geographic expansion into Mumbai, Delhi NCR, and Northeast markets, supported by new hospital openings and digital initiatives.
- Revenue grew 2.2% QoQ to ₹470 in Q1FY27.
- ⚠️ 1) Execution risk in scaling new hospitals to breakeven within tight timelines, particularly in competitive markets like Mumbai and NCR. 2) Margin pre
📖 The Story
Rainbow Children's Medicare is in a high-growth phase, executing a disciplined expansion strategy to scale its pediatric super-specialty network from 1,862 to 5,000 beds by 2031. Management is targeting 20% annual revenue growth through geographic expansion into Mumbai, Delhi NCR, and Northeast markets, supported by new hospital openings and digital initiatives. The company maintains strong profitability with ROCE at 27.1% and zero debt, while reinvesting cash reserves into capex-driven growth. Financial results show consistent revenue and PAT growth, with margins under pressure slightly due to scale-up investments.
📰 What's Happening
In Q1 FY27, Rainbow Children's Medicare reported 33% YoY revenue growth to INR 470 crores and 16% PAT growth to INR 62.5 crores, driven by expansion across 13 cities and 24 locations. The company added new hospitals in Malad, Nellore, and Guntur, with operations at the Mumbai facility expected to commence in Q1 FY28. Capex of INR 2,200 crores will fund the 5,000-bed expansion target by 2031, with cash reserves at INR 613 crores as of June 2026. Management highlighted accreditations (JCI, NABH) and strategic acquisitions like Prashanthi and Pratiksha Hospitals to strengthen its hub-and-spoke model.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 445 | 445 | 460 | 470 |
| Operating Profit | 113 | 107 | 104 | 92 |
| OPM % | 25.4% | 24.1% | 22.6% | 19.7% |
| Net Profit | 76 | 74 | 78 | 63 |
| EPS | ₹7.41 | ₹7.14 | ₹7.59 | ₹5.97 |
Revenue has grown sequentially from ₹445 crores in Sep 2025 to ₹470 crores in Jun 2026, with PAT rising from ₹76 crores to ₹62.5 crores despite a slight dip in EPS. EBITDA margin declined 71 bps to 28.6% in Q1 FY27, which management attributes to scale-up investments. The company is trading off short-term margin expansion for long-term volume growth, as evidenced by 28% inpatient discharge and 25% outpatient consultation growth. The consistent beat in revenue and PAT growth across filings confirms execution of its expansion roadmap.
🔮 Management Outlook & What's Next
Management expects EBITDA margin to expand to 24-25% by FY27-FY28 as scale improves profitability, targeting 20% annual revenue growth to double the top line in ~4 years. The 5,000-bed network by 2031 is central to this vision, with new hospitals in Mumbai, Nellore, and Guntur progressing toward breakeven. Capex of INR 2,200 crores will be deployed over five years, supported by strong cash reserves. Management emphasized that accreditations and digital initiatives are key enablers for operational efficiency and patient retention.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 102 | 102 | 102 | 102 |
| Reserves | 1,242 | 1,367 | 1,416 | 1,568 |
| Borrowings | 760 | 764 | 816 | 0 |
| Total Liabilities | 2,262 | 2,377 | 2,587 | 2,775 |
| Fixed Assets | 1,403 | 1,388 | 1,451 | 1,759 |
| Investments | 423 | 571 | 416 | 405 |
| Total Assets | 2,262 | 2,377 | 2,587 | 2,775 |
The balance sheet shows a strong capital structure with zero net debt and equity reserves of INR 1,568 crores as of Mar 2026. Borrowings remain minimal at INR 816 crores, indicating conservative leverage. Cash reserves of INR 613 crores as of June 2026 provide flexibility for ongoing capex without external financing. The company is funding its expansion through internal cash flows and reserves, reducing financial risk while maintaining a disciplined capital allocation approach.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +420 |
| Investing | -259 |
| Financing | -147 |
| Net Cash Flow | +14 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 49.9% | 49.8% | 49.8% | 49.8% |
| FII | 21.9% | 19.2% | 17.2% | 16.0% |
| DII | 17.5% | 19.5% | 21.1% | 22.6% |
| Public | 10.1% | 10.5% | 10.7% | 10.4% |
| # Shareholders | 81,134 | 88,809 | 88,561 | 89,305 |
Institutional investors hold 55.8% combined stake (FII 16.03%, DII 22.56%), with promoter holding steady at 49.84%. FII and DII holdings have slightly declined from Q2FY26 (21.85% and 17.46%) to Q1FY27 (16.03% and 22.56%), suggesting minor rebalancing. The number of shareholders has grown from 81,134 to 89,305, indicating retail interest. No promoter pledging is reported, and institutional accumulation appears stable, with no signs of exit. The growing shareholder base supports liquidity and governance scrutiny.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 61.0 | 22.1% | 22.9% | 0.60 |
| MANIPALHOS | 1.00 L Cr | — | — | — | 1.25 |
| MAXHEALTH | 99,174 | 68.0 | 14.4% | 13.6% | 0.27 |
| FORTIS | 68,550 | 65.4 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 65,881 | 122.3 | 17.2% | 11.9% | 0.21 |
| MEDANTA | 39,854 | 71.6 | 21.9% | 16.3% | 0.10 |
| NH | 38,979 | 47.5 | 13.7% | 18.0% | 1.07 |
| LALPATHLAB | 32,521 | 46.8 | 29.6% | 21.8% | 0.00 |
| KIMS | 31,685 | 147.9 | 9.7% | 8.7% | 1.44 |
| POLYMED | 17,871 | 56.7 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Execution risk in scaling new hospitals to breakeven within tight timelines, particularly in competitive markets like Mumbai and NCR. 2) Margin pressure from aggressive capex deployment and potential cost overruns in expansion. 3) Dependence on hospital occupancy and payer mix in tier-II cities, which may have lower reimbursement rates. 4) Leadership transition risk following CFO resignation, which could delay financial planning if not managed smoothly.
📋 Recent Filings
-
🟡 Board Meeting 25 August 2026Rainbow Children's Medicare announced the resignation of CFO Vikas Maheshwari effective August 31, 2026, due to personal reasons. The board accepted t...
-
🟡 Board Meeting 25 August 2026No summary available
-
🔴 Financial Results 4 August 2026Rainbow Children's Medicare reported 33% YoY revenue growth to INR 470 crores and 29.9% YoY EBITDA growth to INR 134.6 crores in Q1 FY27, with PAT ris...
-
Announcement 31 July 2026Rainbow Children's Medicare held an earnings conference call on July 31, 2026 to discuss Q1 FY27 results, with the audio recording made publicly avail...
-
🔴 Financial Results 30 July 2026Rainbow Children's Medicare reported Q1 FY27 revenue of **₹4,699.9 crores** and PAT of **[amount context mismatch] crores**, reflecting **13.4% YoY** ...
-
🔴 Financial Results 30 July 2026Rainbow Children's Medicare reported Q1 FY26-27 revenue growth of 11.1% and EBITDA growth of 11.4% year-on-year, driven by expansion in its pediatric ...
-
Announcement 30 July 2026Rainbow Children's Medicare announced on July 30, 2026 that its Nomination and Remuneration Committee granted 2,570 stock options to Anshuman Jaiswal ...
-
🔴 Announcement 30 July 2026Rainbow Children's Medicare announced its unaudited standalone and consolidated financial results for Q1 June 2026, showing revenue of **₹4,233 crores...
-
🟡 Board Meeting 30 July 2026Rainbow Children's Medicare approved unaudited Q1 FY26 standalone results showing 25% revenue growth to [amount not verified] and 7% PAT growth to ₹52...
-
🔴 Financial Results 30 July 2026Rainbow Children's Medicare reported revenue of **₹4,700 crores** for Q1 FY27, a **33.2% YoY** increase, driven by strong hospital growth and operatio...
🧠 Analyst's Read
Rainbow Children's Medicare is executing a clear, capital-intensive growth strategy with strong operational momentum and improving scale. The key watchpoint is whether new hospital additions can ramp up efficiently and contribute to margin expansion by FY28. With healthy cash reserves, zero debt, and institutional backing, the company is well-positioned, but investor patience will be tested on the path to 5,000 beds and sustained profitability.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when RAINBOW files new disclosures
Track RAINBOW filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track RAINBOW — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd